Home » Stocks » iCAD, Inc.

iCAD, Inc. (ICAD)

Stock Price: $9.75 USD 0.34 (3.61%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
After-hours: $10.34 +0.59 (6.05%) Oct 19, 6:47 PM

Stock Price Chart

Key Info

Market Cap 223.28M
Revenue (ttm) 29.36M
Net Income (ttm) -20.51M
Shares Out 22.90M
EPS (ttm) -1.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $9.75
Previous Close $9.41
Change ($) 0.34
Change (%) 3.61%
Day's Open 9.51
Day's Range 9.50 - 9.90
Day's Volume 127,379
52-Week Range 5.91 - 15.31

More Stats

Market Cap 223.28M
Enterprise Value 208.30M
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 22.90M
Float 20.96M
EPS (basic) -1.02
EPS (diluted) -1.01
FCF / Share -0.39
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.10M
Short Ratio 4.49
Short % of Float 5.23%
Beta 1.35
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.61
PB Ratio 8.13
Revenue 29.36M
Operating Income -10.11M
Net Income -20.51M
Free Cash Flow -8.62M
Net Cash 14.98M
Net Cash / Share 0.65
Gross Margin 83.88%
Operating Margin -34.44%
Profit Margin -69.90%
FCF Margin -29.35%
ROA -14.27%
ROE -109.73%
ROIC -133.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$14.50*
(48.72% upside)
Low
12.5
Current: $9.75
High
16.0
Target: 14.50
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue31.3425.6228.1026.3441.5543.9233.0728.2828.6524.58
Revenue Growth22.32%-8.83%6.7%-36.62%-5.4%32.83%16.95%-1.32%16.59%-
Gross Profit24.2319.4318.1818.5229.3531.2323.0920.0320.0319.69
Operating Income-6.40-8.13-14.17-9.97-30.080.82-1.78-5.41-37.12-6.54
Net Income-13.55-9.02-14.26-10.10-32.45-1.01-7.61-9.37-37.59-6.22
Shares Outstanding18.3816.6916.3415.9315.6914.1010.8410.8010.919.17
Earnings Per Share-0.74-0.54-0.87-0.63-2.07-0.07-0.70-0.87-3.45-0.68
Operating Cash Flow-7.11-3.87-7.34-5.48-1.903.20-1.43-4.20-10.140.21
Capital Expenditures-0.30-0.30-0.39-0.34-0.93-1.21-0.54-0.67-0.26-0.32
Free Cash Flow-7.40-4.17-7.73-5.82-2.831.99-1.97-4.87-10.41-0.12
Cash & Equivalents15.3112.199.398.5915.2832.2211.8813.954.5816.94
Total Debt22.4913.105.980.091.0611.6715.8814.85--
Net Cash / Debt-7.18-0.923.418.5014.2320.55-4.00-0.904.5816.94
Assets41.7531.7432.1338.6548.6493.7758.9259.9951.7695.59
Liabilities36.6824.8417.8613.6115.8930.9937.5432.3315.7122.38
Book Value5.076.9014.2825.0432.7562.7821.3827.6736.0673.21
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name iCAD, Inc.
Country United States
Employees 135
CEO Michael S. Klein

Stock Information

Ticker Symbol ICAD
Stock Exchange NASDAQ
Sector Healthcare
Industry Health Information Services
Unique Identifier NASDAQ: ICAD
IPO Date December 3, 1986

Description

iCAD provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Platform, a server residing on a customer's network that receives patient studies from the imaging modality, performs analysis, and sends results to picture archiving and communication system and/or review workstations. In addition, the company offers magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.